A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4)

Brief description of study

The purpose of the study is to determine the safety of bb2121 in patients with high risk, newly diagnosed Multiple Myelorna (NDMM). bb2121 is a CAR-T cellular product directed against the B-cell maturation antigen, which is expressed on the surface of myeloma cells. We want to know what is the optimal dose of bb2121 which may include lowering dose, continuation of the same dose, delay or termination of dosing, repetition of a dose level. bb2121 is an investigational drug, which means it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.

Clinical Study Identifier: s20-00129
ClinicalTrials.gov Identifier: NCT04196491

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.